What SAYANA PRESS Treats: Main Uses and Benefits

Key Symptom Management and Benefits

The primary therapeutic utility of this subcutaneous injection is relevant for easing symptoms related to heightened physiological activity and providing long-term supportive management for family planning. The medication is applied across domains where additional symptomatic support is needed and is commonly used to help with long-term protection. Primary indications include providing continuous contraception and the management of endometriosis-associated pain.

---

This medicine is an established option that assists with maintaining functional stability and is used to provide protection against unintended pregnancy. The active ingredient is also applied in addressing symptom clusters that become more disruptive during flare-ups, specifically in clinical settings that involve managing endometriosis-associated pain and alleviating heavy or excessive menstrual bleeding. A common benefit is that it may assist with the reduction in blood loss, which can lead to the cessation of monthly periods (amenorrhea), supporting general well-being during symptomatic phases. This therapeutic approach is relevant in conditions characterized by periods of heightened symptoms, and may be part of symptomatic management when symptoms interfere with routine activities.

---

Quick Fact: Supportive Management for Disruptive Menstrual Patterns The medication is frequently used in situations involving certain distressing symptoms related to menstrual flow, contributing to improved comfort during symptomatic periods.

Regulatory References

1. FDA DailyMed label for Depo-SubQ Provera 104 (Medroxyprogesterone Acetate)

Who Can and Cannot Use SAYANA PRESS: Official Regulatory Information

SAYANA PRESS (medroxyprogesterone acetate) is an injectable contraceptive primarily for use in females of child-bearing potential, including adolescents after they have begun menstruating. However, its use is governed by official contraindications and specific health warnings.

---

Populations Prohibited from Use (Contraindicated):

• Known or suspected pregnancy.
• Unexplained vaginal bleeding.
• Severe liver dysfunction or significant liver disease.
• Known or suspected hormone-dependent cancer (such as breast or genital organ malignancy).
• Active thromboembolic disease (e.g., deep vein thrombosis) or a history of cerebrovascular disease.
• Known hypersensitivity or allergy to medroxyprogesterone acetate or any of its ingredients.

---

Restrictions and Special Considerations:

• Duration of Use: Use for longer than two years is generally not recommended for contraception unless other methods are considered unsuitable, due to the risk of Bone Mineral Density (BMD) loss.
• Adolescents: Use in adolescents is only indicated when other contraceptive methods are considered unsuitable or unacceptable, as this is a critical period of bone accretion.
• Postpartum: If breast-feeding, the first injection should be given no sooner than six weeks postpartum. If not breast-feeding, it should be given within five days postpartum.
• Medical Conditions: Caution and monitoring are required for patients with a history of venous thromboembolism (VTE), diabetes, clinical depression, and those with risk factors for osteoporosis (e.g., metabolic bone disease, chronic alcohol or tobacco use).

SAYANA PRESS Interactions with other medicines and products

The official interaction profile for Medroxyprogesterone Acetate (MPA), the active ingredient in SAYANA PRESS, is fundamentally structured around pharmacokinetic interactions that alter the medicine's concentration in the body.

---

Interaction Scope

Property	Description
Medicinal product categories with documented interactions:	Medicines that induce or inhibit the cytochrome P450 3A4 (CYP3A4) enzyme.
Specific interacting medicines (if explicitly listed):	Aminoglutethimide (documented to significantly depress serum concentrations); strong CYP3A inducers (e.g., Rifampin, Phenytoin, Carbamazepine, Phenobarbital); and strong CYP3A inhibitors (e.g., Ketoconazole, Itraconazole).
Mechanistic basis of interactions (only if stated in label):	Pharmacokinetic interaction due to MPA being metabolized primarily by hydroxylation via the CYP3A4 isoenzyme in vitro.
Population-specific interaction notes (if applicable):	Hepatic Impairment: The effect of severe liver disease on MPA disposition is unknown, but poor metabolism is anticipated due to the drug's hepatic elimination.
Interaction-related restrictions:	Co-administration with strong CYP3A inducers or inhibitors should be avoided as per regulatory advisories to manage the risk of altered MPA concentrations.

---

Resulting Interaction Structure

Official interaction statements:

• Strong CYP3A Inducers are expected to decrease MPA concentrations, which is the key practical implication for reduced contraceptive effectiveness.
• The specific agent Aminoglutethimide is formally documented to significantly depress MPA serum concentrations.
• The herbal product St. John’s wort (Hypericum perforatum) is listed as an enzyme inducer that may decrease the effectiveness of contraceptive products.
• Strong CYP3A Inhibitors are expected to increase MPA concentrations.

The regulatory profile is defined by metabolic interactions which identify co-administered substances that may either decrease or increase MPA plasma exposure. This focus on altered drug exposure determines the official constraints and warnings documented in the product labeling.

SAYANA PRESS, containing medroxyprogesterone acetate (MPA), functions as a synthetic progestin and agonist at the intracellular progesterone receptor (PR). Following subcutaneous administration, the depot formulation provides sustained release of MPA into the systemic circulation. System-level consequences result from central and peripheral actions.

At the hypothalamic-pituitary-ovarian axis, MPA binding to the PR in the hypothalamus and pituitary gland inhibits the pulsatile secretion of gonadotropin-releasing hormone (GnRH) and subsequently suppresses the release of luteinizing hormone (LH) and follicle-stimulating hormone (FSH). This downstream cascade prevents the final maturation of ovarian follicles. The blunted LH surge consequently blocks the process of ovulation.

Peripherally, MPA directly modifies the cervical and uterine environment. It induces glandular changes in the cervix, causing an increase in the viscosity of the cervical mucus to a thick, impenetrable state. Within the uterus, MPA drives the transformation of the endometrium into an asynchronous, atrophic secretory state by modulating gene transcription, thus rendering it non-receptive to certain biological processes.

How to use SAYANA PRESS: Administration Guidelines

This section outlines the standardized protocol for administering SAYANA PRESS.

---

Administration Scope

Feature	Requirement
Route of administration	The medicine is formulated exclusively for Subcutaneous (SC) injection into the fatty tissue of the upper anterior thigh or abdomen, and it is not intended for intramuscular use.
Dosing schedule	A fixed dose of 104 mg Medroxyprogesterone Acetate (MPA) in a 0.65 mL suspension is required for each administration.
Preparation requirements	The pre-filled device must be vigorously shaken for approximately one minute immediately prior to use to ensure a uniform dose suspension.

---

Frequency and Procedural Constraints

The established usage pattern for SAYANA PRESS is intermittent and defined by strict timing rules.

Classification	Pattern
Frequency pattern	The dose must be administered on a standard interval of every 12 to 14 weeks.
Initiation Timing	The first injection must be given only during the first 5 days of a normal menstrual cycle, or at or after the sixth post-partum week if the patient is breastfeeding.
Duration Constraint	Continuous use is not recommended for longer than 2 years unless other contraceptive methods are judged inadequate.

---

Procedural Structure

The protocol defines the conditions for maintaining the established dose regimen:

• The injection site should be rotated with every subsequent dose between the upper anterior thigh and the abdomen.
• If the scheduled interval exceeds 14 weeks, the patient must be confirmed as non-pregnant before the next dose is administered.
• No dose adjustment is required based on the patient’s body weight.

These instructions establish the precise steps, timing, and conditions that structure the use of the medicine over the long term, ensuring the integrity of the standardized dosing protocol.

Research Evidence / Overview of Studies for SAYANA PRESS

---

Evidence for Use in Pregnancy Prevention (Contraception)

The primary clinical evidence for this injection comes from large, international Phase 3 Clinical Trials that were designed to study reproductive health outcomes in populations of women of childbearing age. Research examined the performance of this subcutaneous (under the skin) formulation by comparing it to the older, established intramuscular (in the muscle) injection. Outcomes monitored included the cumulative pregnancy rate over time, which is a key measure tracked in contraception studies.

Dedicated pharmacokinetic (PK) studies were also conducted. These research efforts was studied to monitor if drug concentrations were maintained at levels research has explored in relation to its intended effect. Findings describe the serum concentration patterns observed in the studies. Drug levels were monitored throughout the typical dosing interval.

What remains uncertain involves the long-term characterization of its use. While the core studies typically followed participants for up to two years, there is limited information regarding outcomes from data collected beyond that period. Research monitored outcomes such as the time interval required for the return of ovulation after discontinuing the injection. Findings indicate that this time frame may vary considerably between individuals.

---

Evidence for Use in Managing Endometriosis-Associated Pain

The use of this medicine in conditions involving periods of heightened symptoms, such as endometriosis, was evaluated in research exploring patient-reported outcomes. The research structure included Randomized, Evaluator-Blind Trials where the injection was observed in comparison to other active hormonal treatments. Research explored episodes where symptoms become more noticeable, examining outcomes measured by pain rating scales during the menstrual cycle (dysmenorrhea) and pain outside of the cycle (non-menstrual pelvic pain).

Findings describe patterns observed in the studies where outcomes related to patient-reported discomfort were measured using standardized scales. Reported changes were tracked relative to the active hormonal comparator used in the trial over the core treatment phase, which was typically six months. These findings describe group patterns observed in the studies.

Data are still emerging regarding sustained effects once treatment ends. Evidence derived from settings with varying symptom burdens indicates that symptoms can recur after the follow-up durations were limited. Long-term effects are not fully established, and observational studies report how symptoms evolved in the observed populations.

---

Research on the Self-Administration Method

The subcutaneous formulation was evaluated in studies specifically examining the practical aspects of its delivery, particularly the option for a patient to administer the injection herself (self-injection). These Randomized Controlled Trials (RCTs) and feasibility studies focused on outcomes reflecting daily functioning or activity level, such as contraceptive continuation rates at 6 and 12 months.

Studies explored participant satisfaction and adherence to the schedule, comparing women who self-injected versus those who received the injection from a healthcare provider. Findings describe patterns observed in the studies where continuation rates were observed in some studies to be similar to or higher in the groups who self-administered. Findings describe group patterns, not personal outcomes, helping to contextualize how patients reported their experience and how adherence patterns evolved.

Key Studies & References

1. Return to fertility after subcutaneous depot medroxyprogesterone acetate: a narrative review

Common questions about SAYANA PRESS (FAQ)

Q: How quickly does SAYANA PRESS start working after the first injection?

Official administration guidelines detail the precise timing of the first dose. Official guidelines specify that the first injection is administered only during the first five days of a normal menstrual cycle, or within five days postpartum if the patient is not breastfeeding, which is done to provide contraceptive coverage starting from the first day of injection.

Q: How does the pre-filled injection system of SAYANA PRESS work?

The pre-filled device is a single-use injection system designed to deliver the medicine in a fixed, subcutaneous dose. Official instructions state the device is to be vigorously shaken immediately prior to use to help ensure the contents are uniformly suspended for proper administration.

Q: Can over-the-counter pain relievers interact with SAYANA PRESS?

Regulatory documents primarily focus on specific medicines that can alter the concentration of the active ingredient through a metabolic pathway called the CYP3A4 enzyme system. Common over-the-counter pain relievers are generally not listed in official regulatory labeling as interacting with this medicine.

Q: Can SAYANA PRESS be used by people who have never had children?

Official product information confirms that the medicine is indicated for use in all females of child-bearing potential. There are no specific restrictions or contraindications listed based on whether an individual has previously given birth.

Q: What is the main difference between SAYANA PRESS and Depo-Provera?

Both medicines contain the same active ingredient, Medroxyprogesterone Acetate (MPA). The primary differences noted in regulatory documents relate to the formulation: SAYANA PRESS is administered subcutaneously (under the skin) at a dose of 104 mg, while the intramuscular formulation is administered intramuscularly (in the muscle) at a 150 mg dose.

Q: Is it normal to feel tired or fatigued after a SAYANA PRESS injection?

Official safety information includes reports of effects such as fatigue or tiredness, sometimes referred to as asthenia, from individuals using the medicine. These effects are documented and categorized in the official product labeling regarding undesirable effects.

Q: Why is SAYANA PRESS administered as an injection instead of a pill?

The product is formulated as a depot suspension for injection to achieve a long-acting effect. This injection is formulated as a depot and is designed to release the active ingredient slowly and consistently from the injection site over the entire 12- to 14-week dosing period, providing continuous contraceptive protection.

Q: Can common antibiotics reduce the effectiveness of SAYANA PRESS?

The interactions listed in regulatory documents focus on medicines that significantly alter the drug's metabolism via the CYP3A4 enzyme system. The antibiotic Rifampin is specifically noted as a potential enzyme inducer that may reduce effectiveness. However, many common antibiotics are not listed as causing this type of interaction.

Q: Does the time of day matter when receiving a SAYANA PRESS injection?

Official guidelines for administering the medicine focus on the timing relative to the menstrual cycle or postpartum period to ensure efficacy. The official instructions do not stipulate a required time of day (morning or evening) for the injection to be administered.

Q: Are there any reports of mood changes or emotional side effects with SAYANA PRESS?

Official safety documents include warnings regarding patients with a history of clinical depression. Furthermore, depressed mood is listed as one of the reported side effects observed either in clinical studies or during post-marketing use of the medicine.

Q: Does official research cover the use of SAYANA PRESS in people with a higher BMI?

The official administration protocol states that no adjustment to the dose is required based on the patient's body weight. This is based on clinical development indicating the standard dose is appropriate across the body weight ranges studied.

Q: Do studies suggest any specific dietary factors that interact with SAYANA PRESS?

Regulatory documents detailing drug interactions focus on pharmaceutical or herbal products that influence the drug's metabolism through the CYP3A4 enzyme system. Specific food or dietary components are not typically listed among the interacting substances in official labeling.

Q: Are there specific official classifications for the effectiveness of SAYANA PRESS?

Official product information classifies the medicine as highly effective for pregnancy prevention. This classification is supported by research that reports the medicine's effectiveness based on measures like the cumulative pregnancy rate observed in clinical trials.

Q: Does the effectiveness of SAYANA PRESS change over long periods of use?

Official documents do not contain specific warnings indicating that the medicine's contraceptive effectiveness decreases over the recommended period of continuous use. Long-term use warnings noted in regulatory sources are instead focused on the risk of Bone Mineral Density (BMD) loss.

Q: Is it possible to receive SAYANA PRESS from a non-clinic setting, such as a pharmacy?

Official research has been conducted to support the feasibility of patients administering the injection themselves (self-administration). This is the official basis that allows the product to potentially be provided and administered outside of a traditional clinical setting, subject to local regulatory guidelines.

Q: Can travel or changes in altitude impact the effectiveness of SAYANA PRESS?

Official product labeling and safety warnings do not list environmental factors, such as travel, altitude, or climate changes, as having an impact on the stability, release, or contraceptive effectiveness of the medicine.

Q: Can SAYANA PRESS affect my ability to get pregnant later on?

Official research indicates that the time required for fertility to return after the last injection is highly variable among individuals. The median time to the return of ovulation is noted to be generally longer with this method compared to certain other contraceptives.

Q: Are there specific vitamins or supplements that should not be taken with SAYANA PRESS?

Regulatory documents specifically warn against the use of the herbal product St. John’s wort, as it may reduce the medicine's effectiveness. However, official regulatory labeling does not typically list common vitamins or general mineral supplements as interacting substances for this medicine.

Q: What should I do if I experience unexpected bruising at the injection site?

Official product information notes that local injection site reactions are a possible effect. These reactions may include pain, tenderness, or the formation of small, temporary nodules. Bruising (ecchymosis) is sometimes observed in clinical study populations receiving injections.

Q: What are the benefits of the subcutaneous injection route used by SAYANA PRESS?

The subcutaneous (SC) route of administration is formulated to use a smaller injection volume and a lower dose of the active ingredient compared to the intramuscular version. Official research has also explored the practicality and feasibility of using this SC method for self-administration.

Q: How is SAYANA PRESS described in terms of its reversibility?

SAYANA PRESS is classified as a Long-Acting Reversible Contraceptive (LARC). While the medicine is reversible, official research notes that the return to fertility after the last injection is variable and may be delayed for several months.

Q: How long does the drug stay in the body after the last injection?

Pharmacokinetic (PK) studies examine how the drug travels and is processed by the body. According to official PK data, the active ingredient is released slowly from the injection site and maintains effective concentrations throughout the intended dosing period. After the scheduled period, the concentration decreases gradually over time based on the drug’s defined elimination profile.

How to Store and Dispose of SAYANA PRESS

SAYANA PRESS (medroxyprogesterone acetate) must be stored and disposed of according to official regulatory requirements to ensure product integrity and safety.

Storage Conditions

Item	Requirement
Temperature	Store at room temperature, specifically below 30 C.
Prohibitions	Do not refrigerate and do not freeze.
Protection	Keep out of the sight and reach of children.
Container	Store in the original sealed foil pouch and do not use after the expiry date.

Disposal Instructions

For disposal, the used injector is a single-dose container and must not be reused. It must be immediately disposed of into a suitable sharps container in accordance with local regulatory authority requirements. Unused or expired medicine must not be discarded in household waste or wastewater; individuals are directed to consult a pharmacist for guidance on proper disposal.